Imaging is expensive. It always sounds like an amazing addition to a study, especially when you see the pictures and the data that it provides. Considering orthotopics can be more relevant models, you want to say YES, but when you see the price, you almost can’t say NO fast enough.

We want to tell you why it is a key component to preclinical oncology studies.

Presenter

  • Vivek Mahajn, PhD, Research Scientist, Charles River